 |
86 Diseases |  |
33 Trials |
|
33 Trials |  |
1474 News |  |
| «12...6789101112131415161718» |
- | Pletal (cilostazol) / Otsuka
Clinical, Journal: DAPT Plus Cilostazol is Better Than Traditional DAPT or Aspirin Plus Ticagrelor as Elective PCI for Intermediate-to-Highly Complex Cases: Prospective, Randomized, PRU-Based Study in Taiwan. (Pubmed Central) - May 30, 2019
P=N/A
Clopidogrel appears safer than ticagrelor in Taiwanese patients with stable angina after stent implantation for intermediate-to-highly complex coronary lesions. The addition of cilostazol to clopidogrel may provide a more rapid decrease in PRU to therapeutic levels without increasing the risk of hemorrhage.
- | Pletal (cilostazol) / Otsuka
Review, Journal: Development of a Multicomponent Intervention to Prevent Alzheimer's Disease. (Pubmed Central) - May 30, 2019
The COMCID (Cilostazol for prevention of Conversion from MCI to Dementia) trial, evaluating the efficacy of cilostazol for patients with mild cognitive impairment is currently ongoing in Japan. Such therapeutic approaches involving maintenance of cerebrovascular integrity and promotion of vascular-mediated Aβ clearance have the potential to be mainstream treatments for sporadic AD.
- | Pletal (cilostazol) / Otsuka
Journal: Insights into the potential antidepressant mechanisms of cilostazol in chronically restraint rats: impact on the Nrf2 pathway. (Pubmed Central) - May 30, 2019
Cilostazol also prevented the decrease in the hippocampal activities of mitochondrial respiratory enzyme complexes I-IV. These behavioral and biochemical findings indicated the potential prophylactic antidepressant effect and mechanism of cilostazol by preventing oxidative stress by activation of redox defense mechanisms mediated through the Nrf2 pathway and restoring mitochondrial dysfunction.
- | Pletal (cilostazol) / Otsuka
Clinical, Journal: Risk factors for restenosis after drug-coated balloon angioplasty for complex femoropopliteal arterial occlusive disease. (Pubmed Central) - May 29, 2019
However, the primary patency continuously deteriorated beyond 1 year, suggesting a late catch-up phenomenon. The risk of restenosis after treatment with DCBs was significantly associated with CLI and hypercholesterolemia.
- | Pletal (cilostazol) / Otsuka, Adexor (trimetazidine) / Egis
Clinical, Journal: Comparison of efficacy between trimetazidine and cilostazol in the treatment of arteriosclerosis obliterans in lower extremity. (Pubmed Central) - May 16, 2019
The clinical efficacy of cliostazol in the treatment of ASO had a good effect, and there was only a few adverse reactions and the long-term survival rate was high. It is worthy of being promoted in clinical practice.
- || Pletal (cilostazol) / Otsuka
Genetic screening Cilostazol/bepridil (Twitter) - May 16, 2019
- | Pletal (cilostazol) / Otsuka
Clinical, Journal: The safety of triple antiplatelet therapy under thromboelastography guidance in patients undergoing stenting for ischemic cerebrovascular disease. (Pubmed Central) - May 15, 2019
TAT under TEG guidance appears to be a safe antiplatelet strategy in patients undergoing stenting for extracranial and/or intracranial artery stenosis. By employing TAT under TEG guidance, favorable outcomes can be achieved in these patients.
- || cilostazol / Generic mfg.
Trial completion: Bioequivalence Study of Once Daily PMR Compared to Twice Daily Cilostazol IR Tablets in Healthy Volunteers (clinicaltrials.gov) - May 13, 2019
P1, N=28, Completed, Sponsor: Genovate Biotechnology Co., Ltd.,
By employing TAT under TEG guidance, favorable outcomes can be achieved in these patients. Active, not recruiting --> Completed
- ||| Pletal (cilostazol) / Otsuka
Thx for all replies! @djc795: Glad u brought it up. My IC fellow made a joke about BVS & then we kicked around ideas ranging from BVS to Papyrus (bad idea), oral rapamycin, cilostazol (CREST) & re-CABG when ISR comes back. Basic issue is barbed wire poking into the RCA wall. (Twitter) - May 13, 2019
- | Pletal (cilostazol) / Otsuka
Preclinical, Journal: Cilostazol as a chemically induced preclinical model of migraine. (Pubmed Central) - May 11, 2019
Active, not recruiting --> Completed No abstract available
- | Pletal (cilostazol) / Otsuka
Clinical, P2a data, Journal: Preventing cognitive decline and dementia from cerebral small vessel disease: The LACI-1 Trial. Protocol and statistical analysis plan of a phase IIa dose escalation trial testing tolerability, safety and effect on intermediary endpoints of isosorbide mononitrate and cilostazol, separately and in combination. (Pubmed Central) - May 7, 2019
P2
Discussion This study will inform the design of a larger phase III trial of isosorbide mononitrate and cilostazol in lacunar stroke, whilst providing data on the drugs' effects on vascular and platelet function. Trial registration ISRCTN (ISRCTN12580546) and EudraCT (2015-001953-33).
- | Pletal (cilostazol) / Otsuka
Journal: Cilostazol Improves HFD-induced Hepatic Steatosis by Upregulating Hepatic STAMP2 Expression Through AMPK. (Pubmed Central) - May 7, 2019
Cilostazol ameliorates hepatic steatosis by enhancing hepatic STAMP2 expression through AMPK. Enhancing STAMP2 expression with cilostazol represents a potential therapeutic avenue for treatment of NAFLD.
- | Pletal (cilostazol) / Otsuka
Clinical, Journal: Comparison of 1-Year Outcomes of Triple (Aspirin + Clopidogrel + Cilostazol) Versus Dual Antiplatelet Therapy (Aspirin + Clopidogrel + Placebo) After Implantation of Second-Generation Drug-Eluting Stents into One or More Coronary Arteries: from the DECREASE-PCI Trial. (Pubmed Central) - May 1, 2019
However, the rates of TVR were significantly lower in the triple antiplatelet therapy group than in the dual antiplatelet therapy group (HR 0.118; 95% CI 0.015 to 0.930; p = 0.043). In conclusion, triple antiplatelet therapy with cilostazol after implantation of second-generation DES improved clinical outcomes, mainly by reducing TVR.
- | Pletal (cilostazol) / Otsuka
Journal: Cilostazol-Loaded Poly(ε-Caprolactone) Electrospun Drug Delivery System for Cardiovascular Applications. (Pubmed Central) - Apr 30, 2019
In conclusion, triple antiplatelet therapy with cilostazol after implantation of second-generation DES improved clinical outcomes, mainly by reducing TVR. The release profile of CIL and nanomechanical properties of all formulations of PCL fibers demonstrate that the cilostazol loaded PCL fibers are an efficient delivery system for vascular implant application.
- | Pletal (cilostazol) / Otsuka
Journal: Effects of açaí and cilostazol on skin microcirculation and viability of TRAM flaps in hamsters. (Pubmed Central) - Apr 30, 2019
The release profile of CIL and nanomechanical properties of all formulations of PCL fibers demonstrate that the cilostazol loaded PCL fibers are an efficient delivery system for vascular implant application. Açaí and cilostazol treatments had a protective effect against ischemic damage to TRAM flaps in hamsters, improving microvascular blood flow and increasing the survival of flap zones contralateral to the vascular pedicle (zones III and IV).
- | fondaparinux / generics
Clinical, Journal: Responsible, Safe, and Effective Use of Antithrombotics and Anticoagulants in Patients Undergoing Interventional Techniques: American Society of Interventional Pain Physicians (ASIPP) Guidelines. (Pubmed Central) - Apr 30, 2019
Açaí and cilostazol treatments had a protective effect against ischemic damage to TRAM flaps in hamsters, improving microvascular blood flow and increasing the survival of flap zones contralateral to the vascular pedicle (zones III and IV). Based on the survey of current literature, and published clinical guidelines, recommendations for patients presenting with ongoing antithrombotic therapy prior to interventional techniques are variable, and are based on comprehensive analysis of each patient and the risk-benefit analysis of intervention.
- | Pletal (cilostazol) / Otsuka
P4 data, Journal: Antithrombotic therapy after femoropopliteal artery stenting: 12-month results from Japan Postmarketing Surveillance. (Pubmed Central) - Apr 30, 2019
Clinical benefits of DAPT or cilostazol might be small in terms of TLR and MACCE at 12 months. Anticoagulation with warfarin at discharge might increase TLR at 12 months.
- | Clinical, Journal: Is there a role for oral triple therapy in patients with acute coronary syndromes without atrial fibrillation? (Pubmed Central) - Apr 26, 2019
More potent antithrombotic regimens increase bleeding and should only be considered on an individual basis, after careful risk stratification. Accurate risk stratification of ACS patients, for both ischaemic and bleeding risk, is essential to allow individualised treatment.
- | Pletal (cilostazol) / Otsuka
Journal: Cardiovascular Disease: Lower Extremity Peripheral Artery Disease. (Pubmed Central) - Apr 22, 2019
Patients with acute limb ischemia should be referred emergently for evaluation and possible revascularization. Patients with lifestyle-limiting claudication despite lifestyle modification and medical therapy and patients with chronic limb ischemia (eg, nonhealing wounds) should be considered for revascularization.
- | cilostazol / Generic mfg.
Phase classification: Cilostazol Stroke Prevention Study for Antiplatelet Combination (clinicaltrials.gov) - Apr 20, 2019
P4, N=1884, Completed, Sponsor: Japan Cardiovascular Research Foundation
Patients with lifestyle-limiting claudication despite lifestyle modification and medical therapy and patients with chronic limb ischemia (eg, nonhealing wounds) should be considered for revascularization. Phase classification: P3 --> P4
- | Pletal (cilostazol) / Otsuka
Clinical, Journal: Cilostazol may improve cognition better than clopidogrel in non-surgical adult patients with ischemic moyamoya disease: subanalysis of a prospective cohort. (Pubmed Central) - Apr 19, 2019
Phase classification: P3 --> P4 Cilostazol may improve cognition better than clopidogrel in non-surgical adult patients with ischemic MMD.
- | cilostazol / Generic mfg.
Trial completion date, Trial primary completion date: DORIC: Diabetic Artery Obstruction: is it Possible to Reduce Ischemic Events With Cilostazol? (clinicaltrials.gov) - Apr 18, 2019
P4, N=1885, Recruiting, Sponsor: University of Ioannina
Cilostazol may improve cognition better than clopidogrel in non-surgical adult patients with ischemic MMD. Trial completion date: Oct 2018 --> Oct 2019 | Trial primary completion date: Apr 2018 --> Oct 2019
- | Pletal (cilostazol) / Otsuka
Preclinical, Journal: Supratherapeutic concentrations of cilostazol inhibits β-amyloid oligomerization in vitro. (Pubmed Central) - Apr 11, 2019
CSZ (25-100 μM) inhibited Aβ aggregation, especially oligomer formation. Considering that CSZ might be a key molecule for DMTs of AD, it cannot be ruled out that the low concentration of CSZ achievable in patient dosing may display some ant-oligomeric activity in synergy with its known therapeutic effects.
- | Pletal (cilostazol) / Otsuka
Preclinical, Journal: Potentiation of imatinib by cilostazol in sensitive and resistant gastrointestinal stromal tumor cell lines involves YAP inhibition. (Pubmed Central) - Apr 9, 2019
Verteporfin, a YAP/TEAD interaction inhibitor, reduced by 90% the viability of both GIST882 and GIST48 cells. Our results highlight the potential use of compounds targeting PDE3A or YAP in combined multitherapy to tackle GIST resistance.
- | Pletal (cilostazol) / Otsuka, Livalo (pitavastatin) / Kowa, Eli Lilly
Journal: In vitro analysis of drugs that improve hyperglycemia-induced blood-brain barrier dysfunction. (Pubmed Central) - Apr 3, 2019
Our results highlight the potential use of compounds targeting PDE3A or YAP in combined multitherapy to tackle GIST resistance. In summary, pitavastatin and candesartan improved HG-induced BBB damage and this in vitro model of HG-induced BBB dysfunction contributes to the search for BBB protective drugs.
- ||| Pletal (cilostazol) / Otsuka
Clinical: In addition to all the excellent suggestions, I would add cilostazol. We have had very good results in such patients. (Twitter) - Apr 1, 2019
- | Pletal (cilostazol) / Otsuka
Retrospective data, Review, Journal: Stent thrombosis associated with drug eluting stents on addition of cilostazol to the standard dual antiplatelet therapy following percutaneous coronary intervention: a systematic review and meta-analysis of published randomized controlled trials. (Pubmed Central) - Mar 27, 2019
In summary, pitavastatin and candesartan improved HG-induced BBB damage and this in vitro model of HG-induced BBB dysfunction contributes to the search for BBB protective drugs. This current analysis showed no significant difference in stent thrombosis with the addition of cilostazol to the standard dual antiplatelet therapy during any follow-up time period after PCI.
- | Pletal (cilostazol) / Otsuka
Preclinical, Journal, IO Biomarker: Cilostazol disrupts TLR-4, Akt/GSK-3β/CREB, and IL-6/JAK-2/STAT-3/SOCS-3 crosstalk in a rat model of Huntington's disease. (Pubmed Central) - Mar 25, 2019
In conclusion the present study provided a new insight into the possible mechanisms by which cilostazol possesses neuroprotective properties. These intersecting mechanisms involve the interference between TLR-4, IL-6-IL-10/JAK-2/STAT-3/SOCS-3, and Akt/GSK-3β/CREB signalling pathways.
- | Pletal (cilostazol) / Otsuka
Clinical, Journal: Prevention of cardiovascular events in Asian patients with ischaemic stroke at high risk of cerebral haemorrhage (PICASSO): a multicentre, randomised controlled trial. (Pubmed Central) - Mar 23, 2019
P4
In patients with ischaemic stroke at high risk of cerebral haemorrhage, cilostazol was non-inferior to aspirin for the prevention of cardiovascular events, but did not reduce the risk of haemorrhagic stroke. Addition of probucol to aspirin or cilostazol could be beneficial for reducing the incidence of cardiovascular events.
- | cilostazol / Generic mfg.
Trial completion date: Effect of Cilostazol on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes (clinicaltrials.gov) - Mar 15, 2019
P4, N=50, Active, not recruiting, Sponsor: Seoul National University Bundang Hospital
Addition of probucol to aspirin or cilostazol could be beneficial for reducing the incidence of cardiovascular events. Trial completion date: Dec 2018 --> Dec 2019
- | cilostazol / Generic mfg.
Enrollment closed: A Trial of Cilostazol in Patients With Mild Cognitive Impairment (COMCID) (clinicaltrials.gov) - Mar 13, 2019
P2, N=200, Active, not recruiting, Sponsor: National Cerebral and Cardiovascular Center
Trial completion date: Dec 2018 --> Dec 2019 Recruiting --> Active, not recruiting
- || cilostazol / Generic mfg.
New P1 trial: Bioequivalence Study of Once Daily PMR Compared to Twice Daily Cilostazol IR Tablets in Healthy Volunteers (clinicaltrials.gov) - Mar 6, 2019
P1, N=28, Active, not recruiting, Sponsor: Genovate Biotechnology Co., Ltd.,
- | sildenafil / Generic mfg.
New P2 trial: OxHARP: Oxford Haemodynamic Adaptation to Reduce Pulsatility Trial (clinicaltrials.gov) - Feb 26, 2019
P2, N=75, Not yet recruiting, Sponsor: University of Oxford
- | cilostazol / Generic mfg.
Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date: Comparison of Cilostazol-based Triple Antiplatelet Therapy Versus Dual Antiplatelet Therapy for Outcomes of below-the Knee Endovascular Intervention in Patients With Critical Limb Ischemia (TAP CLI Study) (clinicaltrials.gov) - Jan 14, 2019
P4, N=390, Recruiting, Sponsor: Yonsei University
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Trial completion date: Dec 2019 --> Oct 2021 | Initiation date: Jul 2016 --> Feb 2017 | Trial primary completion date: Sep 2019 --> Oct 2021
- ||||||| cilostazol / Generic mfg.
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Cilostazol Stroke Prevention Study for Antiplatelet Combination (clinicaltrials.gov) - Dec 27, 2018
P3, N=1884, Completed, Sponsor: Japan Cardiovascular Research Foundation
Not yet recruiting --> Recruiting | Trial completion date: Dec 2019 --> Oct 2021 | Initiation date: Jul 2016 --> Feb 2017 | Trial primary completion date: Sep 2019 --> Oct 2021 Recruiting --> Completed | N=4000 --> 1884 | Trial completion date: Mar 2017 --> Dec 2018 | Trial primary completion date: Mar 2017 --> Dec 2018
- | Trial initiation date: Comparison of Two Different Antiplatelet Preparations for an Unruptured Intracranial Aneurysm (clinicaltrials.gov) - Nov 30, 2018
P4, N=176, Recruiting, Sponsor: Seoul National University Hospital
Recruiting --> Completed | N=4000 --> 1884 | Trial completion date: Mar 2017 --> Dec 2018 | Trial primary completion date: Mar 2017 --> Dec 2018 Initiation date: Jul 2018 --> Oct 2018
- | cilostazol / Generic mfg.
Trial termination: Cilostazol After Lower Extremity Arterial Revascularization Trial (clinicaltrials.gov) - Nov 23, 2018
P4, N=20, Terminated, Sponsor: Wake Forest University Health Sciences
Initiation date: Jul 2018 --> Oct 2018 Completed --> Terminated; Original PI left institution
- | cilostazol / Generic mfg.
Enrollment closed: Effect of Cilostazol on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes (clinicaltrials.gov) - Oct 24, 2018
P4, N=50, Active, not recruiting, Sponsor: Seoul National University Bundang Hospital
Completed --> Terminated; Original PI left institution Recruiting --> Active, not recruiting
- | cilostazol / Generic mfg.
Trial completion date, Trial primary completion date: SILOAM: Efficacy and Safety of Adjunctive Cilostazol in Acute Myocardial Infarction Patients (clinicaltrials.gov) - Aug 8, 2018
P4, N=951, Recruiting, Sponsor: Korea University Guro Hospital
Recruiting --> Active, not recruiting Trial completion date: Jul 2018 --> Feb 2019 | Trial primary completion date: Jul 2018 --> Feb 2019
- | cilostazol / Generic mfg.
Trial completion: Comparative Pharmacokinetic Study Between Two Extended-Release Cilostazol Formulations in Korea (clinicaltrials.gov) - Jul 24, 2018
P1, N=30, Completed, Sponsor: Bundang CHA Hospital
Trial completion date: Jul 2018 --> Feb 2019 | Trial primary completion date: Jul 2018 --> Feb 2019 Recruiting --> Completed
- | cilostazol / Generic mfg.
Trial completion: Pharmacokinetic Study of Once Daily PMR Compared to Twice Daily Cilostazol IR Tablets in Healthy Volunteers (clinicaltrials.gov) - Jul 10, 2018
P1, N=21, Completed, Sponsor: Genovate Biotechnology Co., Ltd.,
Recruiting --> Completed Active, not recruiting --> Completed
- | New P4 trial: Comparison of Two Different Antiplatelet Preparations for an Unruptured Intracranial Aneurysm (clinicaltrials.gov) - Jul 9, 2018
P4, N=176, Recruiting, Sponsor: Seoul National University Hospital
- | aspirin / Generic mfg., cilostazol / Generic mfg.
Trial primary completion date: CILO-PER: Cilostazol Following Peripheral Endovascular Procedures (clinicaltrials.gov) - Jun 27, 2018
P3, N=200, Recruiting, Sponsor: Attikon Hospital
Active, not recruiting --> Completed Trial primary completion date: Dec 2018 --> Jun 2019
- | cilostazol / Generic mfg.
New P1 trial: Comparative Pharmacokinetic Study Between Two Extended-Release Cilostazol Formulations in Korea (clinicaltrials.gov) - May 18, 2018
P1, N=30, Recruiting, Sponsor: Bundang CHA Hospital
- || cilostazol / Generic mfg.
Enrollment closed, Trial completion date, Trial primary completion date: Pharmacokinetic Study of Once Daily PMR Compared to Twice Daily Cilostazol IR Tablets in Healthy Volunteers (clinicaltrials.gov) - May 3, 2018
P1, N=21, Active, not recruiting, Sponsor: Genovate Biotechnology Co., Ltd.,
Trial primary completion date: Dec 2018 --> Jun 2019 Recruiting --> Active, not recruiting | Trial completion date: Oct 2018 --> May 2018 | Trial primary completion date: Sep 2018 --> May 2018
- | cilostazol / Generic mfg.
New P1 trial: Pharmacokinetic Study of Once Daily PMR Compared to Twice Daily Cilostazol IR Tablets in Healthy Volunteers (clinicaltrials.gov) - Mar 29, 2018
P1, N=21, Recruiting, Sponsor: Genovate Biotechnology Co., Ltd.,
- ||| cilostazol / Generic mfg.
Enrollment closed, Trial completion date, Trial primary completion date: CAS-CARE: Carotid Artery Stenting With Cilostazol Addition for Restenosis (clinicaltrials.gov) - Mar 7, 2018
P4, N=900, Active, not recruiting, Sponsor: Kobe City General Hospital
Recruiting --> Active, not recruiting | Trial completion date: Oct 2018 --> May 2018 | Trial primary completion date: Sep 2018 --> May 2018 Enrolling by invitation --> Active, not recruiting | Trial completion date: Mar 2016 --> Mar 2019 | Trial primary completion date: Mar 2014 --> Mar 2017
- | isosorbide mononitrate / Generic mfg., cilostazol / Generic mfg.
Trial completion, Trial initiation date: Prevent-SVD: Lacunar Intervention Trial 1 (LACI-1) (clinicaltrials.gov) - Jan 19, 2018
P2, N=57, Completed, Sponsor: University of Edinburgh
Enrolling by invitation --> Active, not recruiting | Trial completion date: Mar 2016 --> Mar 2019 | Trial primary completion date: Mar 2014 --> Mar 2017 Recruiting --> Completed | Initiation date: Oct 2015 --> Mar 2016
- | aspirin / Generic mfg., cilostazol / Generic mfg.
New P3 trial: Cilostazol-Aspirin Therapy Against Recurrent Stroke With Intracranial Artery Stenosis (clinicaltrials.gov) - Dec 19, 2017
P3, N=200, Completed, Sponsor: Translational Research Informatics Center, Kobe, Hyogo, Japan
- | cilostazol / Generic mfg.
Trial completion, Enrollment change, Trial initiation date, Trial primary completion date: Comparison of Primary Long Full Coverage Stenting vs Primary Short Spot Stenting for Long Femoropopliteal Artery Disease. (clinicaltrials.gov) - Nov 28, 2017
P=N/A, N=89, Completed, Sponsor: Yonsei University
Recruiting --> Completed | Initiation date: Oct 2015 --> Mar 2016 Recruiting --> Completed | N=220 --> 89 | Initiation date: Mar 2011 --> Sep 2011 | Trial primary completion date: Mar 2016 --> Aug 2017